Featured
New Currents
Read More
• Both vonoprazan-based treatment regimens demonstrated superior eradication rates vs. a standard of care proton pump inhibitor (PPI)-based triple therapy • New Drug Application (NDA) […]
PHILADELPHIA, PA, April 6, 2021 — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific, announced today that the Company completed a […]
FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel […]
Topline results expected in second half of 2021 FLORHAM PARK, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage […]
San Francisco, Calif., July 16, 2020 Company Focused on Developing New Medicines for Postoperative Delirium and Other Inflammatory Disorders Domain Associates and Catalys Pacific today […]
Tokyo, Japan – December 9, 2019 Catalys Pacific announced Hito (Hidehito) Kotani has joined the team at Catalys Pacific as Operating Partner. He will focus […]
BUFFALO GROVE, Ill.–(BUSINESS WIRE)–Oct. 24, 2019– Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal […]
Catalys Pacific is delighted to announce that, on July 16th, 2019, Founder & Managing Partner of Catalys Pacific, Dr. BT Slingsby, received the Japanese Foreign […]
Tokyo, Japan – 17 June 2019 Catalys Pacific, a new venture capital firm in Japan built by a global team seasoned in life sciences investing, […]
